Atlas Trials

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Clinical trial NCT03233217 · COMPLETED

Trial details

NCT number
NCT03233217
Sponsor
Sanofi Pasteur, a Sanofi Company
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Influenza
Start date
2017-09-15
Primary completion
2017-11-28
Enrollment
175

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.